Sitagliptin for early Parkinson's disease
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests whether sitagliptin, a diabetes drug, can slow the progression of early Parkinson's disease. It aims to see if the medication can protect brain cells and reduce symptoms, potentially offering a new way to treat Parkinson's.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 80 years old.
- You have been diagnosed with Parkinson's disease within the last 3 years.
- You are not yet taking Parkinson's medication, or you are on a stable dose of levodopa only (no other Parkinson's drugs) for at least 12 weeks.
- Your Parkinson's symptoms are mild (Hoehn and Yahr stage 1 or 2) when you are taking your medication.
- You have had a special brain scan (DAT scan) that shows reduced dopamine in a specific brain area, or you are willing to have one.
- You have had a brain MRI to confirm your diagnosis and rule out other causes.
- You have no severe memory problems (MMSE score 24 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
This trial tests if metformin, a diabetes drug, can help people with Parkinson's disease. It may improve symptoms or slow progression.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.
This trial tests whether vildagliptin, a diabetes drug, can slow the progression of early Parkinson's disease. It is for people who have been diagnosed within the past three years and are already taking stable Parkinson's medications.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.